Ehni, Hans-Jörg (1969- )
Ehni, Hans-Jörg.
Hans-Jörg Ehni
VIAF ID: 74152282 (Personal)
Permalink: http://viaf.org/viaf/74152282
Preferred Forms
- 200 _ | ‡a Ehni ‡b Hans-Jörg ‡f 1969-....
- 100 1 _ ‡a Ehni, Hans-Jörg
- 100 1 _ ‡a Ehni, Hans-Jörg ‡d 1969-
- 100 1 _ ‡a Ehni, Hans-Jörg, ‡d 1969-
-
- 100 1 _ ‡a Ehni, Hans-Jörg
-
-
- 100 0 _ ‡a Hans-Jörg Ehni
4xx's: Alternate Name Forms (6)
5xx's: Related Names (5)
- 510 2 _ ‡a Eberhard Karls Universität Tübingen ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Eberhard Karls Universität Tübingen ‡b Institut für Ethik und Geschichte der Medizin ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Hans-Neuffer-Stiftung
- 551 _ _ ‡a Tübingen ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _ ‡a Universität Tübingen
Works
Title | Sources |
---|---|
Abhandlung über das Argumentieren | |
Advanced old age as a developmental dilemma: An in-depth comparison of established fourth age conceptualizations | |
Altersutopien medizinische und gesellschaftliche Zukunftshoffnungen der Lebensphase Alter | |
‘Better see a doctor?’ status quo of symptom checker apps in Germany a cross-sectional survey with a mixed-methods design (CHECK.APP) | |
The definition of adequate care in externally sponsored clinical trials: the terminological controversy about the concept "standard of care" | |
Deklaration von Helsinki Revisionen und Kontroversen | |
Dual use and the ethical responsibility of scientists. | |
Equity and healthy ageing | |
Ethics codes and medical decision making | |
Ethics codes and use of new and innovative drugs | |
Ethics review in compassionate use | |
Ethik der Biogerontologie | |
Expensive cancer drugs and just health care. | |
Fading red lines? Bioethics of germline genome editing | |
For the sake of "normality"? Medical indication, social justification, and the welfare of children | |
Globalization in medical research | |
International ethical regulations on placebo-use in clinical trials: a comparative analysis. | |
moralisch Böse Überlegungen nach Kant und Ricoeur | |
Die neue Rhetorik. Bd. 1 / Chaim Perelman, Lucie Olbrechts-Tyteca. - Stuttgart-Bad Cannstatt, 2004. | |
The normative dimensions of extending the human lifespan by age-related biomedical innovations. | |
On moral enhancement from a Habermasian perspective | |
Patterns of biomedical science production in a sub-Saharan research center | |
Reconsidering the Declaration of Helsinki | |
Reply to "Innovation and off-label use, the French case and more" by Braillon and Lexchin | |
Research ethics for a globalised world: the revised CIOMS international guidelines. | |
Rhetorik | |
Saving the most lives-A comparison of European triage guidelines in the context of the COVID-19 pandemic | |
Toward a global geroethics - gerontology and the theory of the good human life. | |
Traité de l'argumentation | |
Vita brevis, ars longa aktuelle Perspektiven zu Geschichte, Theorie und Ethik der Medizin | |
Zukunftsvisionen des Alters Fragen und Antworten der Philosophie und Ethik |